Macrophage Markers Market Size, Share & Trends Analysis Report By Marker Type (CD68, CD163, CD206, CD14, CD11b, CD64, CD11c, Others), By Application (Research Use, Diagnostic Use and Drug Development), By Disease Area (Oncology, Infectious Diseases, Autoimmune Diseases, Cardiovascular Diseases, Neurological Disorders, Others), By End User, By Region, And By Segment Forecasts, 2023-2031
Macrophage Markers Market Size is valued at USD 240.64 Million in 2022 and is predicted to reach USD 439.65 Million by the year 2031 at a 7.11% CAGR during the forecast period for 2023-2031.
Macrophage markers are distinct molecules or proteins utilized for identifying and characterising macrophages, a particular type of immune cell responsible for guarding the body against infections and foreign substances. These indicators aid researchers and doctors in differentiating macrophages from other cell types and comprehending their roles in diverse tissues and circumstances. Macrophages commonly studied and isolated for research or diagnostic purposes can be identified using certain cell surface proteins. These proteins, such as CD14, CD68, and CD163, are frequently employed in laboratory procedures like flow cytometry or immunohistochemistry.
The ongoing research in immunology and inflammation fuels the demand for tools and reagents such as macrophage markers. As we get a better understanding of macrophage biology, there is a rising demand for more specific and sensitive markers to characterise macrophage subtypes and roles.
The COVID-19 pandemic has profoundly affected numerous businesses, particularly the life sciences and healthcare sectors. The pandemic caused laboratory operations to be disrupted, including research project delays, academic institution closures, and decreased access to research resources. This slowed the speed of macrophage marker-related research.
Competitive Landscape
Some Major Key Players In The Macrophage Markers Market:
- Abcam plc
- Bio-Rad Laboratories, Inc.
- Cell Signaling Technology, Inc.
- BD Biosciences
- Thermo Fisher Scientific, Inc.
- Agilent Technologies, Inc.
- BioLegend, Inc.
- Merck KGaA
- Novus Biologicals, LLC
- R&D Systems, Inc. (a Bio-Techne brand)
- Santa Cruz Biotechnology, Inc.
- Beckman Coulter, Inc.
- Miltenyi Biotec GmbH
- GeneTex, Inc.
- MBL International Corporation
- Others
Market Segmentation:
The Macrophage Markers Market is segmented on the basis of marker type, application, disease area, and end-use. Based on the marker type, the market is segmented as CD68, CD163, CD206, CD14, CD11b, CD64, CD11c, and Others. The application segment includes Research Use, Diagnostic Use, and Drug Development. According to disease area, the market is segmented into Oncology, Infectious Diseases, Autoimmune Diseases, Cardiovascular Diseases, Neurological Disorders, and Others. The end-user segment includes Research Institutes and Academic Centers, Pharmaceutical and Biotechnology Companies, Clinical and Diagnostic Laboratories, and Others.
Based On Marker Type, The CD68 Segment Is A Major Contributor In The Macrophage Markers Market.
The CD68 category is expected to hold a major share in the global Macrophage Markers Market in 2022. Several factors influence the market for CD68 markers, notably in the context of macrophages, and contribute to its growth and development. CD68 is a glycoprotein that is abundant in macrophages and is often employed as a tissue macrophage marker. Immunology and inflammatory research are important drivers of the CD68 markers industry. Because macrophages play an important role in immune response and inflammatory processes, there is a significant demand for markers like CD68 for researching and characterising these cells in various situations.
Personal Care Segment Witnessed A Rapid Growth.
The personal care segment is estimated to grow at a rapid rate in the global Macrophage Markers Market. Macrophage markers are critical in oncology for understanding the role of macrophages in tumour genesis, progression, and response to treatment. In the tumour microenvironment, macrophages are a prominent component of the immune infiltration. TAMs can have pro- or anti-tumoral effects, and understanding their function is critical for creating targeted cancer therapeutics. The necessity to characterise TAMs in various malignancies drives the desire for macrophage markers. Imaging technology, flow cytometry, and molecular biology approaches have improved the precision and efficiency of macrophage marker analysis.
In The Region, The North American Macrophage Markers Market Holds A Significant Revenue Share.
The North American macrophage Markers Market is expected to record the maximum market revenue share in the near future. The increased frequency of cancer and other chronic diseases, rising demand for cell-based therapeutics, and expanding immunology research efforts are driving the expansion of this market. The demand for macrophage markers is being fueled by ongoing research in immunology, cancer biology, and inflammatory illnesses. Academic institutions, research institutes, and pharmaceutical businesses in North America are currently engaged in studies into the functions of macrophages in different health situations. Furthermore, the Asia Pacific region is estimated to experience significant growth in the worldwide Macrophage Markers Market. Research and development endeavors in several scientific fields have experienced a substantial rise in the Asia Pacific area. The demand for macrophage markers is fueled by the growing investment in life sciences research from universities, research organizations, and pharmaceutical companies.
Recent Developments:
- In Dec 2021, Carisma Therapeutics partnered with Merck (known as MSD outside the US and Canada) to conduct a clinical study. The study aims to assess the effectiveness of Carisma's targeted chimeric antigen receptor macrophages (CAR-M) in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for treating cancers that overexpress human epidermal growth factor receptor 2 (HER2).
Macrophage Markers Market Report Scope
| Report Attribute | Specifications |
| Market Size Value In 2022 | USD 240.64 Million |
| Revenue Forecast In 2031 | USD 439.65 Million |
| Growth Rate CAGR | CAGR of 7.11% from 2023 to 2031 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
| Historic Year | 2019 to 2022 |
| Forecast Year | 2023-2031 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Marker Type, Disease Area, Application, End-User |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
| Competitive Landscape | Abcam plc, Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., BD Biosciences, Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., BioLegend, Inc., Merck KGaA, Novus Biologicals, LLC, R&D Systems, Inc. (a Bio-Techne brand), Santa Cruz Biotechnology, Inc., Beckman Coulter, Inc., Miltenyi Biotec GmbH, GeneTex, Inc., MBL International Corporation and Others. |
| Customization Scope | Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Segmentation of Macrophage Markers Market-
Macrophage Markers Market By Marker Type-
- CD68
- CD163
- CD206
- CD14
- CD11b
- CD64
- CD11c
- Others
Macrophage Markers Market By Application-
- Research Use
- Diagnostic Use
- Drug Development
Macrophage Markers Market By Disease Type-
- Oncology
- Infectious Diseases
- Autoimmune Diseases
- Cardiovascular Diseases
- Neurological Disorders
- Others
Macrophage Markers Market By End-User-
- Research Institutes and Academic Centers
- Pharmaceutical and Biotechnology Companies
- Clinical and Diagnostic Laboratories
- Others
Macrophage Markers Market By Region-
North America-
- The US
- Canada
- Mexico
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Macrophage Markers Market Size is valued at USD 240.64 Million in 2022 and is predicted to reach USD 439.65 Million by the year 2031
Macrophage Markers Market expected to grow at a 7.11% CAGR during the forecast period for 2023-2031.
Santa Cruz Biotechnology, Inc., Beckman Coulter, Inc., Miltenyi Biotec GmbH, GeneTex, Inc., MBL International Corporation and Others
Marker Type, Disease Area, Application and End-User are the key segments of the Macrophage Markers Market.
North American region is leading the Macrophage Markers Market.